A comprehensive review in “Biofunct. Mater.” meticulously details the most recent advancements and clinical translation of intelligent nanodrugs for breast cancer treatment. This paper presents an exhaustive overview of subtype-specific nanostrategies, the clinical benefits of FDA-approved nanodrugs, and innovative approaches to address tumor heterogeneity and treatment resistance. This serves as a foundational framework and pragmatic guide for enhancing precision-based breast cancer therapies.
Breast cancer, the most common cancer among women worldwide, is a major therapeutic challenge because of its profound heterogeneity. Breast cancer can be classified into several molecular subtypes, such as Luminal A, HER2-positive, and triple-negative breast cancer (TNBC), and a treatment that is effective for one patient may not work for another. In addition to this intrinsic heterogeneity, drug resistance and serious side effects have prompted the pursuit of more accurate and precise therapeutic strategies.
Nanomedicine, utilizing engineered nanoparticles for targeted drug delivery to tumors, presents a promising avenue for future treatment strategies. However, the design of an appropriate nanocarrier for individual patients has historically been a complex and often inefficient process of trial and error. The multitude of potential design parameters, including size, surface charge, and targeting ligand density, leads to a combinatorial explosion that is not feasible to test experimentally.
In this review, researchers from Shanghai Jiao Tong University School of Medicine and Guangdong Medical University have proposed a novel, data-driven solution to address the aforementioned challenge. They introduce an “AI-multi-omics intelligent delivery paradigm,” in which a machine learning model is utilized to predict the optimal design of nanocarriers. This prediction is based on the unique biological signatures specific to a patient’s tumor.
We have transitioned from a universal, one-size-fits-all methodology to a subtype-specific, intelligent drug delivery system. Many studies demonstrate that the incorporation of multi-omics data with artificial intelligence can effectively simplify complex processes. For example, in the case of aggressive Luminal B tumors, our model significantly enhanced the synchronization between drug release and peak tumor proliferation rates, increasing it by a factor of 2.8 compared to traditional static nanocarriers.”
Meng-Yao Li, corresponding author
The review methodically delineates the manner in which this paradigm capitalizes on subtype-specific vulnerabilities. In the case of HER2-positive breast cancer, the utilization of trastuzumab-conjugated dendrimers resulted in a reduction of off-target toxicity by 47%. For the treatment of TNBC, a notoriously difficult-to-treat subtype, the employment of EGFR-antibody liposomes amplified tumor accumulation by a factor of 3.2.
The study also presents a comprehensive review of the current state of clinical nanomedicine, ranging from FDA-approved drugs such as Doxil®-which significantly decreases the cardiotoxicity of doxorubicin from 18% to 3%-to promising therapies currently under clinical trials. Notably, preliminary results for ²²⁵Ac-liposomes indicate that 77.8% of patients with metastatic TNBC achieved stable disease status for a duration of six months or longer, without any observed bone marrow toxicity.
“The potential is profound,” elucidates Yimao Wu, a co-first author of the review. “This transcends mere incremental advancements. It offers a viable roadmap to engineer health, morphing breast cancer from a perilous disease into a manageable condition via personalized nanotherapeutic intervention.”
The authors recognize that issues related to large-scale manufacturing and long-term safety continue to impede clinical adoption. Nevertheless, with the incorporation of AI, multi-omics data, and biomimetic nanocarriers such as exosomes, the trajectory of breast cancer treatment is on course to be notably more accurate and efficacious in the future.
This paper ‘Intelligent delivery and clinical transformation of nanomedicine in breast cancer: from basic research to individualized therapy’ was published in Biofunctional Materials (ISSN: 2959-0582), an online multidisciplinary open access journal aiming to provide a peer-reviewed forum for innovation, research and development related to bioactive materials, biomedical materials, bio-inspired materials, bio-fabrications and other bio-functional materials.
Wu, Y., et al. (2025) Intelligent delivery and clinical transformation of nanomedicine in breast cancer: from basic research to individualized therapy. Biofunctional Materials, https://doi.org/10.55092/bm20250014.
News
AI’s promise and practical limits in drug discovery
AI tools are becoming increasingly common in early drug discovery, allowing scientists to analyse data and navigate large volumes of research. However, according to Dr Raminderpal Singh, turning that potential into consistent scientific workflows [...]
GHCE Concept
From the preface of the book Global Health Care Equivalency in the Age of Nanotechnology, Nanomedicine and Artificial Intelligence, Edited by Frank Boehm: Since the publication of my first book (Nanomedical Device and Systems [...]
Healthcare Headlines: Challenges and Advances in 2026
Health-related updates reveal financial adjustments by Universal Health Services due to Medicaid reimbursement uncertainties, significant pollution-linked health concerns from French-British oil firm Perenco in Congo, drug trial setbacks, potential restructuring at major medical firms, [...]
Scientists Discover the Brain Protein That Helps Alzheimer’s Spread Through the Brain
Scientists have identified a brain protein that may help Alzheimer’s spread, revealing a potential new target for slowing the disease’s progression. Alzheimer’s disease is closely linked to the accumulation of a toxic form of the protein [...]
How Immune Dysregulation Contributes to Psychiatric Disorders
Introduction Growing evidence suggests that disruptions in immune function may play an important role in the development and progression of psychiatric disorders. However, immune mechanisms probably contribute more strongly in some patients than others, [...]
Electrostatic Discharge Boosts Triboelectric Nanogenerator Current and Enables DC Output
Controlled electrical discharges could enable triboelectric nanogenerators to achieve higher peak currents, extending nano-enabled energy harvesting into chemical processing and self-powered sensing. Paper: Electrostatic discharge as a breakthrough strategy for triboelectric nanogenerators. A new review [...]
Swiss laboratory uses old drugs against rare diseases
Researchers at the University of Geneva are combing through collections of approved drugs to find new therapies for rare diseases – with some success. This approach is gaining traction around the world, while pharmaceutical [...]
Nanozyme Aptasensors Show Promise for Faster Food, Health, and Environmental Testing
By pairing robust artificial enzymes with highly selective aptamers, nanozyme aptasensors could help detect disease biomarkers, pathogens, and contaminants faster, but the review shows that real-world deployment still depends on overcoming matrix interference, biofouling, [...]
Paralyzed Man Feels Sensation Again With Brain Stimulation Device
Aneuroprosthetic system has allowed a man with paralysis to grasp and lift objects and feel touch again. The device helped 42-year-old Keith Thomas of Massapequa, New York, who was paralyzed from the chest down [...]
Global Cancer Cases Could Surge 67% by 2050, New Report Warns
New data reveal major geographic disparities and highlight the urgent need for global action on prevention, early detection, and equitable access to treatment. For roughly one in five people worldwide, cancer will become part [...]
A Deadly Ebola-Like Virus Is Spreading. Are We Ready?
BU virologist Nancy Sullivan says the Bundibugyo outbreak in the Democratic Republic of the Congo underscores the need for broader outbreak preparedness. The death of a nurse marked the moment health officials recognized that [...]
Why Most Animal Viruses Never Become Human Pandemics
From receptor mismatch to risky human-animal interfaces, this article explains why spillover is common but true pandemic emergence remains rare. Introduction Humans are constantly exposed to animal viruses through farming, wildlife contact, and the [...]
Stem cell organoids repair heart microvessels in coronary artery disease models
A Stanford University team has shown that vascular organoids derived from human stem cells can repair the heart’s microvessel network in pigs with ischaemic heart disease – a proof-of-concept advancement that could open new therapeutic [...]
Goodbye GP waiting rooms, hello prevention at home
Prevention is suddenly everywhere in NHS reform. The recent £340m community pharmacy deal is moving more services onto the high street. Community Diagnostic Centres are being expanded, and the Neighbourhood Health Framework sets out [...]
Ebola control is weakened by mistrust and cultural insensitivity
Effective response depends on cooperation with communities and frontline workers, writes Zaeem ul Haq The current Bundibugyo Ebola outbreak in the Democratic Republic of the Congo (DRC) and Uganda is exposing dangerous gaps in [...]
Building the Brain Requires Millions of Dangerous DNA Breaks
Scientists discovered that building a healthy brain involves an unexpected step: young neurons routinely break and rapidly repair their own DNA. As the brain develops, newly formed nerve cells must travel through tightly packed tissue [...]
